drugset / Trial / NCT04880746
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
Phase 3
Unknown
266 enrolled
Ruijin Hospital
Affiliated Zhongshan Hospital of Dalian University · collabFujian Medical University Union Hospital · collabHarbin Hematology and Oncology Institute · collabHuashan Hospital · collabQilu Hospital of Shandong University · collabRenJi Hospital · collabShanxi Province Cancer Hospital · collabThe First Affiliated Hospital of Anhui Medical University · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collabXinqiao Hospital of Chongqing · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This multi-center clinical study will evaluate the efficacy and safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma.
Timeline
- Start
- 2020-10-17
- Primary completion
- 2024-10-17
- Completion
- 2025-10-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | 6 mg/m2 | — |
| Comparator | Cyclophosphamide | Other / unclassified | 1500 mg/m2 | — |
| Comparator | Cytarabine | Small molecule | 100 mg/m2 | — |
| Comparator | Etoposide | Small molecule | 100 mg/m2 | — |
| Comparator | Semustine | Small molecule | 300 mg/m2 | — |